In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.
Prior authorizations are a major burden for practices. How can AI and other technology help physicians in the fight?
Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.
Discover effective strategies to reduce overhead costs in medical practices without layoffs, enhancing staff morale and improving patient care.
Real-world studies reveal GLP-1 medications like semaglutide and tirzepatide yield less weight loss than clinical trials, highlighting treatment discontinuation challenges.
Introduction Among foreign body ingestions in children, button battery ingestion is becoming increasingly common. When the battery is impacted in the oesophagus, the risk of…
The conference offers immersive, peer-driven education tracks designed to help independent pharmacies innovate, adapt, and thrive in a changing health care landscape.
The ACP Advocate is a bi-weekly e-newsletter that provides ACP members with news about public policy issues affecting internal medicine.
New Moneypenny survey shows two-thirds of health care organizations are now using or exploring AI, but concerns over data security, implementation and patient experience remain.
New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.
In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.
